胃食管反流病的新型及未来药物研发
New and future drug development for gastroesophageal reflux disease.
作者信息
Maradey-Romero Carla, Fass Ronnie
机构信息
The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
出版信息
J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30.
Abstract
Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug development for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)'s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.
摘要
药物治疗仍然是胃食管反流病（GERD）最常用的治疗方法。尽管过去几年对GERD药物研发的兴趣有所下降，主要原因是大多数质子泵抑制剂（PPI）转为非专利药和非处方药，但GERD仍存在许多未满足的需求领域。药物研发一直集中在强效组胺2型受体拮抗剂、缓释PPI、PPI联合用药、钾离子竞争性酸阻滞剂、短暂性下食管括约肌松弛抑制剂、促动力药、粘膜保护剂和食管疼痛调节剂。上述化合物可能会针对GERD未满足需求的特定领域，而不是与现有的抗反流疗法竞争。
相似文献
1
New and future drug development for gastroesophageal reflux disease.胃食管反流病的新型及未来药物研发
J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30.
2
Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.治疗胃食管反流病的新疗法：质子泵抑制剂之外。
Curr Gastroenterol Rep. 2020 Mar 17;22(4):16. doi: 10.1007/s11894-020-0753-y.
3
Pharmacological management of GERD: where does it stand now?胃食管反流病的药物治疗管理：现状如何？
Trends Pharmacol Sci. 2011 Apr;32(4):258-64. doi: 10.1016/j.tips.2011.02.007. Epub 2011 Mar 22.
4
Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?综述文章：内镜检查阴性的反流性疾病的诊治方法：属于胃食管反流病范畴还是一种独特的酸相关性疾病？
Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:28-34. doi: 10.1111/j.0953-0673.2004.01835.x.
5
Potassium-competitive acid blockers and gastroesophageal reflux disease.钾离子竞争型酸阻断剂与胃食管反流病。
World J Gastroenterol. 2022 Jul 28;28(28):3608-3619. doi: 10.3748/wjg.v28.i28.3608.
6
ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?质子泵抑制剂治疗后持续出现症状是由于难治性胃食管反流病还是其他疾病？
Arq Gastroenterol. 2018 Nov;55Suppl 1(Suppl 1):85-91. doi: 10.1590/S0004-2803.201800000-48. Epub 2018 Oct 4.
7
Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors.质子泵抑制剂治疗不佳的胃食管反流病的管理。
Curr Opin Gastroenterol. 2010 Jul;26(4):367-78. doi: 10.1097/MOG.0b013e32833ae2be.
8
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.《2015年胃食管反流病循证临床实践指南》
J Gastroenterol. 2016 Aug;51(8):751-67. doi: 10.1007/s00535-016-1227-8. Epub 2016 Jun 21.
9
Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.胃食管反流病症状患者经经验性质子泵抑制剂治疗失败后的多模态评估。
Dis Esophagus. 2013 Jul;26(5):443-50. doi: 10.1111/j.1442-2050.2012.01381.x. Epub 2012 Aug 2.
10
Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy.质子泵抑制剂治疗无效的疑似反流症状的当前诊断与管理
Gastroenterol Hepatol (N Y). 2014 Sep;10(9):547-55.
引用本文的文献
1
Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH Monitoring.右兰索拉唑、泮托拉唑、埃索美拉唑和雷贝拉唑在实现最佳24小时胃内pH值控制方面的疗效比较：一项使用动态pH监测的随机交叉研究。
Cureus. 2024 Oct 14;16(10):e71418. doi: 10.7759/cureus.71418. eCollection 2024 Oct.
2
In Vitro Metabolism and Transport Characteristics of Zastaprazan.扎斯塔拉唑的体外代谢和转运特性
Pharmaceutics. 2024 Jun 13;16(6):799. doi: 10.3390/pharmaceutics16060799.
3
Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.沃克索拉唑10毫克或20毫克与兰索拉唑15毫克用于亚洲糜烂性食管炎愈合患者维持治疗的随机对照试验。
Chin Med J (Engl). 2024 Apr 20;137(8):962-971. doi: 10.1097/CM9.0000000000003068. Epub 2024 Mar 29.
4
Quantitative dose-response analysis untangles host bottlenecks to enteric infection.定量剂量反应分析解开了宿主对肠道感染的瓶颈。
Nat Commun. 2023 Jan 28;14(1):456. doi: 10.1038/s41467-023-36162-3.
5
Proton-Pump Inhibitors Suppress T Cell Response by Shifting Intracellular Zinc Distribution.质子泵抑制剂通过改变细胞内锌分布抑制 T 细胞反应。
Int J Mol Sci. 2023 Jan 7;24(2):1191. doi: 10.3390/ijms24021191.
6
Bridge Swallowing Exercise for Gastroesophageal Reflux Disease Symptoms: A Pilot Study.用于胃食管反流病症状的桥式吞咽练习：一项初步研究。
Prog Rehabil Med. 2022 Oct 8;7:20220054. doi: 10.2490/prm.20220054. eCollection 2022.
7
The effect of adding duloxetine to lansoprazole on symptom and quality of life improvement in patients with gastroesophageal reflux diseases: A randomized double-blind clinical trial.度洛西汀联合兰索拉唑对胃食管反流病患者症状及生活质量改善的影响：一项随机双盲临床试验。
J Res Med Sci. 2021 Jan 28;26:4. doi: 10.4103/jrms.JRMS_300_19. eCollection 2021.
8
Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.A 类 G 蛋白偶联受体拮抗剂法莫替丁作为对抗 SARS-CoV-2 的治疗新选择：一项计算机模拟分析。
Biomolecules. 2020 Jun 24;10(6):954. doi: 10.3390/biom10060954.
9
Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.治疗胃食管反流病的新疗法：质子泵抑制剂之外。
Curr Gastroenterol Rep. 2020 Mar 17;22(4):16. doi: 10.1007/s11894-020-0753-y.
10
Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects.两种替戈拉赞（CJ-12420）制剂在健康男性受试者中的药代动力学特征比较。
Transl Clin Pharmacol. 2019 Jun;27(2):80-85. doi: 10.12793/tcp.2019.27.2.80. Epub 2019 Jun 28.
本文引用的文献
1
Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review.胃食管反流病的流行病学更新：系统评价。
Gut. 2014 Jun;63(6):871-80. doi: 10.1136/gutjnl-2012-304269. Epub 2013 Jul 13.
2
Novel pharmaceutical approaches to reflux disease.治疗反流病的新药物方法。
Gastroenterol Clin North Am. 2013 Mar;42(1):93-117. doi: 10.1016/j.gtc.2012.12.001. Epub 2013 Jan 5.
3
Combination of proton pump inhibitor and rebamipide, a free radical scavenger, promotes artificial ulcer healing after endoscopic submucosal dissection with dissection size >40 mm.质子泵抑制剂联合自由基清除剂瑞巴派特可促进内镜黏膜下剥离术（剥离面积＞40mm）后人工溃疡的愈合。
J Clin Biochem Nutr. 2012 Nov;51(3):185-8. doi: 10.3164/jcbn.12-14. Epub 2012 Jun 8.
4
Burden of gastrointestinal disease in the United States: 2012 update.美国胃肠道疾病负担：2012 年更新。
Gastroenterology. 2012 Nov;143(5):1179-1187.e3. doi: 10.1053/j.gastro.2012.08.002. Epub 2012 Aug 8.
5
Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.雷贝拉唑 200mg+依托必利 150mg 联合治疗的生物利用度和耐受性：一项健康韩国男性志愿者中随机交叉研究。
Clin Ther. 2012 Sep;34(9):1999-2010. doi: 10.1016/j.clinthera.2012.07.004. Epub 2012 Aug 1.
6
TRPV1 antagonists: clinical setbacks and prospects for future development.瞬时受体电位香草酸亚型1拮抗剂：临床挫折与未来发展前景
Prog Med Chem. 2012;51:57-70. doi: 10.1016/B978-0-12-396493-9.00002-9.
7
Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).发现一种新型吡咯衍生物 1-[5-(2-氟苯基)-1-(吡啶-3-基磺酰基)-1H-吡咯-3-基]-N-甲基甲脒富马酸盐（TAK-438）作为钾竞争酸阻滞剂（P-CAB）。
J Med Chem. 2012 May 10;55(9):4446-56. doi: 10.1021/jm300318t. Epub 2012 Apr 30.
8
The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers.新型代谢型谷氨酸受体 5 拮抗剂（AZD2066）对健康志愿者短暂性食管下括约肌松弛和反流事件的影响。
Aliment Pharmacol Ther. 2012 May;35(10):1231-42. doi: 10.1111/j.1365-2036.2012.05081.x. Epub 2012 Apr 2.
9
The effects of nizatidine on transient lower esophageal sphincter relaxations (TLESRs) and acid reflux in healthy subjects.尼扎替丁对健康受试者一过性下食管括约肌松弛（TLESRs）及酸反流的影响。
J Smooth Muscle Res. 2011;47(6):157-66. doi: 10.1540/jsmr.47.157.
10
The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH.每日一次奥美拉唑和琥珀酸（VECAM）与每日一次奥美拉唑对 24 小时胃内 pH 值的影响。
Neurogastroenterol Motil. 2012 May;24(5):426-31, e208-9. doi: 10.1111/j.1365-2982.2012.01884.x. Epub 2012 Feb 28.
Zotero 插件